Oncology firms Oncternal and Tokalas merge
Cancer drug development firms Oncternal Therapeutics Inc. and Tokalas Inc. have merged into one entity which will carry the Oncternal name, and be led by Tokalas CEO Dr. James Breitmeyer. Financial details were not disclosed.
- Acquisition of Private Biotech
- Full Acquisition
- Intra-Biotech Deal
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.